Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Medscape4d
Room-temperature Storage of Medications Labeled for Refrigeration
28 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin) pen fill cartridge Novolog Mix 70/30 pen fill cartridge (Novo Nordisk ...
Benzinga.com1mon
Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns
Posts by the clinics featured images of weight-loss injection pens and direct references to the drugs, violating UK advertising rules. Novo Nordisk denied knowledge of the clinics' promotional ...